Chemo before or after surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares two approaches for patients with pancreatic or periampullary cancer that can be surgically removed: getting chemotherapy before surgery (neoadjuvant therapy) versus surgery first. It aims to find out which sequence leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is in the head of the pancreas or the nearby bile duct area (periampullary).
- The tumor has not spread to major arteries and has only limited contact with veins, meaning it can be fully removed by surgery.
- You are in good overall health (able to perform daily activities and low anesthesia risk).
- You have adequate liver, kidney, and bone marrow function as shown by blood tests.
- You have not had prior surgery or chemotherapy for pancreatic cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This Phase 2 trial tests a combination of immunotherapy (sintilimab) and chemotherapy (nab-paclitaxel and gemcitabine) given before surgery and again after surgery for pancreatic cancer that can be removed (or close to removable). It aims to improve outcomes by shrinking the tumor before the operation and reducing the chance of return after surgery.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.